Analysts at Jones Trading initiated coverage on shares of Theravance Biopharma (NASDAQ:TBPH - Get Free Report) in a report released on Tuesday,Benzinga reports. The firm set a "buy" rating and a $24.00 price target on the biopharmaceutical company's stock. Jones Trading's target price would indicate a potential upside of 123.26% from the stock's current price.
Several other equities analysts have also recently weighed in on TBPH. Wall Street Zen raised Theravance Biopharma from a "hold" rating to a "buy" rating in a report on Wednesday, May 14th. HC Wainwright reissued a "buy" rating and issued a $15.00 target price on shares of Theravance Biopharma in a report on Tuesday, February 25th. Three investment analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to data from MarketBeat.com, Theravance Biopharma has an average rating of "Moderate Buy" and a consensus price target of $14.50.
Check Out Our Latest Stock Report on Theravance Biopharma
Theravance Biopharma Price Performance
TBPH stock opened at $10.75 on Tuesday. The stock has a market capitalization of $537.51 million, a P/E ratio of -10.64 and a beta of -0.09. Theravance Biopharma has a 1-year low of $7.44 and a 1-year high of $11.82. The business has a fifty day moving average price of $9.61 and a 200-day moving average price of $9.45.
Theravance Biopharma (NASDAQ:TBPH - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The biopharmaceutical company reported ($0.27) EPS for the quarter, missing the consensus estimate of ($0.11) by ($0.16). The business had revenue of $15.39 million during the quarter, compared to the consensus estimate of $28.08 million. Theravance Biopharma had a negative return on equity of 24.79% and a negative net margin of 78.18%. As a group, analysts anticipate that Theravance Biopharma will post -1.09 earnings per share for the current year.
Insider Activity at Theravance Biopharma
In other news, SVP Rhonda Farnum sold 24,000 shares of the firm's stock in a transaction dated Monday, June 2nd. The stock was sold at an average price of $11.00, for a total value of $264,000.00. Following the transaction, the senior vice president now owns 336,918 shares of the company's stock, valued at $3,706,098. This trade represents a 6.65% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 6.90% of the stock is owned by company insiders.
Hedge Funds Weigh In On Theravance Biopharma
Large investors have recently added to or reduced their stakes in the company. Invesco Ltd. increased its stake in shares of Theravance Biopharma by 3.5% in the fourth quarter. Invesco Ltd. now owns 46,050 shares of the biopharmaceutical company's stock worth $433,000 after purchasing an additional 1,576 shares in the last quarter. Bank of New York Mellon Corp raised its holdings in Theravance Biopharma by 1.5% during the first quarter. Bank of New York Mellon Corp now owns 117,499 shares of the biopharmaceutical company's stock valued at $1,049,000 after acquiring an additional 1,720 shares during the period. Charles Schwab Investment Management Inc. lifted its position in shares of Theravance Biopharma by 0.7% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 293,936 shares of the biopharmaceutical company's stock valued at $2,766,000 after acquiring an additional 2,060 shares in the last quarter. Rhumbline Advisers lifted its position in shares of Theravance Biopharma by 3.8% in the first quarter. Rhumbline Advisers now owns 62,254 shares of the biopharmaceutical company's stock valued at $556,000 after acquiring an additional 2,293 shares in the last quarter. Finally, Aquatic Capital Management LLC bought a new position in shares of Theravance Biopharma in the fourth quarter worth about $25,000. Hedge funds and other institutional investors own 99.10% of the company's stock.
About Theravance Biopharma
(
Get Free Report)
Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Theravance Biopharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Theravance Biopharma wasn't on the list.
While Theravance Biopharma currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
